EUVIMEDEUVIMED entdecken
Open Access

Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy

Tae Gun Kang iD, Xin Lan iD, Tian Mi iD, Hongfeng Chen iD, Shanta Alli iD, Song-Eun Lim iD, Sheetal Bhatara iD, Anoop Babu Vasandan iD, Grace Ward iD, Sofia Bentivegna iD, Josh Jang iD, Marianne L Spatz iD und 12 weitere

Science · 11.10.2024 · 386 (6718)

DOI: 10.1126/science.adl4492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science, erschienen am 11.10.2024. Verfasst von Tae Gun Kang und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA. Hauptthemen laut MEDLINE: CD8-Positive T-Lymphocytes, Clonal Hematopoiesis, Dioxygenases, DNA Methyltransferase 3A. Die Arbeit wurde bisher 99-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epigenetic reinforcement of T cell exhaustion is known to be a major barrier limiting T cell responses during immunotherapy. However, the core epigenetic regulators restricting antitumor immunity during prolonged antigen exposure are not clear. We investigated three commonly mutated epigenetic regulators that promote clonal hematopoiesis to determine whether they affect T cell stemness and response to checkpoint blockade immunotherapy. CD8 T cells lacking Dnmt3a, Tet2, or Asxl1 preserved a progenitor-exhausted (Tpex) population for more than 1 year during chronic antigen exposure without undergoing malignant transformation. Asxl1 controlled the self-renewal capacity of T cells and reduced CD8 T cell differentiation through H2AK119 ubiquitination and epigenetic modification of the polycomb group–repressive deubiquitinase pathway. Asxl1-deficient T cells synergized with anti–PD-L1 immunotherapy to improve tumor control in experimental models and conferred a survival advantage to mutated T cells from treated patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CD8-Positive T-LymphocytesClonal HematopoiesisDioxygenasesDNA Methyltransferase 3ADNA-Binding ProteinsEpigenesis, GeneticImmune Checkpoint InhibitorsImmunosuppression TherapyProto-Oncogene ProteinsRepressor ProteinsT-Cell ExhaustionAnimalsHumansMiceB7-H1 AntigenCell DifferentiationDNA (Cytosine-5-)-MethyltransferasesHistones

Substanzen

ASXL1 protein, humanB7-H1 AntigenDioxygenasesDNA (Cytosine-5-)-MethyltransferasesDNA Methyltransferase 3ADNA-Binding ProteinsDNMT3A protein, humanDnmt3a protein, mouseHistonesImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Immunology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • College of Graduate Health Sciences, University of Tennessee Health Science Center, Memphis, TN 38105, USA.
  • Department of Computational Biology, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
  • Department of Hematology, Rigshospitalet, Copenhagen University Hospital, DK-2100 Copenhagen, Denmark.
  • Biotech Research and Innovation Center (BRIC), University of Copenhagen, DK-2200 Copenhagen, Denmark.
  • Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA.

ORCID-Profile: Tae Gun Kang, Xin Lan, Tian Mi, Hongfeng Chen, Shanta Alli, Song-Eun Lim, Sheetal Bhatara, Anoop Babu Vasandan, Grace Ward, Sofia Bentivegna, Josh Jang, Marianne L Spatz, Jin-Hwan Han, Balthasar Clemens Schlotmann, Jakob Schmidt Jespersen, Christopher Derenzo, Peter Vogel, Jiyang Yu, Stephen Baylin, Peter Jones, Casey O'Connell, Kirsten Grønbæk, Ben Youngblood, Caitlin C Zebley

Förderung

  • NIAID NIH HHS
  • NCI NIH HHS

Zitieren

APA

Kang, T. G., Lan, X., Mi, T., Chen, H., Alli, S., Lim, S. E., Bhatara, S., Vasandan, A. B., Ward, G., Bentivegna, S., Jang, J., Spatz, M. L., Han, J. H., Schlotmann, B. C., Jespersen, J. S., Derenzo, C., Vogel, P., Yu, J., Baylin, S., …, & Zebley, C. C. (2024). Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy. Science, 386(6718). https://doi.org/10.1126/science.adl4492

Vancouver

Kang TG, Lan X, Mi T, Chen H, Alli S, Lim SE, et al. Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy. Science. 2024;386(6718). doi:10.1126/science.adl4492

BibTeX
@article{Kang2024,
  author = {Kang, Tae Gun and Lan, Xin and Mi, Tian and Chen, Hongfeng and Alli, Shanta and Lim, Song-Eun and Bhatara, Sheetal and Vasandan, Anoop Babu and Ward, Grace and Bentivegna, Sofia and Jang, Josh and Spatz, Marianne L and Han, Jin-Hwan and Schlotmann, Balthasar Clemens and Jespersen, Jakob Schmidt and Derenzo, Christopher and Vogel, Peter and Yu, Jiyang and Baylin, Stephen and Jones, Peter and O'Connell, Casey and Grønbæk, Kirsten and Youngblood, Ben and Zebley, Caitlin C},
  title = {Epigenetic regulators of clonal hematopoiesis control CD8 T cell stemness during immunotherapy},
  journal = {Science},
  year = {2024},
  volume = {386},
  number = {6718},
  doi = {10.1126/science.adl4492}
}
Kostenlos starten →